Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 45, Issue 8, 2004, Pages 1605-1609

  Pocali, Barbara ^a   De Simone, Mariacarla ^a   Annunziata, Mario ^a   Palmieri, Salvatore ^a   D'Amico, Maria Rosaria ^a   Copia, Carolina ^a   Viola, Assunta ^a   Mele, Giuseppina ^a   Schiavone, Ettore Mariano ^a   Ferrara, Felicetto ^a,b  

^a CARDARELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Aggressive non Hodgkin's lymphoma; Autologous stem cell transplantation; IEV regimen

Indexed keywords

CARMUSTINE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; MESNA;

ACUTE PANCREATITIS; ADULT; AGED; ALOPECIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LIVER TOXICITY; LYMPHATIC LEUKEMIA; MALE; MEDICAL ASSESSMENT; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; EPIRUBICIN; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, LYMPHOBLASTIC; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; REMISSION INDUCTION; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 3042857528     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190410001683651     Document Type: Article

References (26)

1. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., et al. (1993) "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma", New England Journal of Medicine, 328, 1002-1006.
2. Couderc, B., Dujols, J.P., Mokhtari, F., Norkowski, J.L., Slawinski, J.C., and Schlaifer, D. (2000) "The management of adult aggressive non-Hodgkin's lymphomas", Critical Review Oncology Hematology, 35, 33-48.
3. Longo, D.L., Duffey, P.L., Young, R.C., Hubbard, S.M., Ihde, D.C., Glatstein, E., et al. (1992) "Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure", Journal of Clinical Oncology, 10, 210-218.
4. Salles, G., Shipp, M.A. and Coiffier, B. (1994) "Chemotherapy of non-Hodgkin's aggressive lymphomas", Seminars in Hematology, 31, 46-69.
5. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., et al. (1995) "Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma", New England Journal of Medicine, 333, 1540-1545.
6. Vose, J.M., Anderson, J.R., Kessinger, A., Bierman, P.J., Coccia, P., Reed, E.C., et al. (1993) "High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma", Journal of Clinical Oncology, 11, 1846-1851.
7. Lin, T.S. and Copelan, E.A. (2003) "Autologous stem cell transplantation for non-Hodgkin's lymphoma", Current Hematolology Reports, 2, 310-315.
8. Gutierrez, M., Chabner, B.A., Pearson, D., Steinberg, S.M., Jaffe, E.S., Cheson, B.D., et al. (2000) "Role of a Doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH", Journal of Clinical Oncology, 18, 3633-3642.
9. Aurlien, E., Holte, H., Pharo, A., Kvaloy, S., Jakobsen, E., Smeland, E.B., et al. (1998) "Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma" , Bone Marrow Transplantation, 21, 873-878.
10. Moskowitz, C.H., Bertino, J.R., Glassman, J.R., Hedrick, E.E., Hunte, S., Coady-Lyons, N., et al. (1999) "Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma", Journal of Clinical Oncology, 17, 3776-3785.
11. Rodriguez, M.A., Cabanillas, F.C., Hagemeister, F.B., McLaughlin, P., Romaguera, J.E., Swan, F., et al. (1995) "A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas", Annals of Oncology, 6, 609-611.
12. Hagemeister, F.B., Tannir, N., McLaughlin, P., Salvador, P., Riggs, S., Velasquez, W.S., et al. (1987) "MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease", Journal of Clinical Oncology, 5, 556-561.
13. Cabanillas, F. (1989) "Experience with ifosfamide combinations in malignant lymphomas", Seminars in Oncology, 16, 78-81.
14. Kingreen, D., Beyer, J., Kleiner, S., Reif, S., Huhn, D. and Siegert, W. (2001) "ICE-an efficient drug combination for stem cell mobilization and high dose treatment of malignant lymphoma", European Journal of Haematology, 66(Suppl 64), 46-50.
15. Zinzani, P.L., Tani, M., Molinari, A.L., Stefani, V., Zuffa, E., Alinari, L., et al. (2002) "Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients", Haematologica, 87, 816-821.
16. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., et al. (1994) "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group", Blood, 84, 1361-1392.
17. Anonymous (1993) "A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project", New England Journal of Medicine, 329, 987-994.
18. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., et al. (1999). "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group" , Journal of Clinical Oncology, 17, 1244-1251.
19. Mills, W., Chopra, R., McMillan, A., Pearce, R., Linch, D.C. and Goldstone, A.H. (1995) "BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma", Journal of Clinical Oncology, 13, 588-595.
20. Kaplan, E.L. and Meier, P. (1958) "Non-parametric estimation from incomplete observations", Journal of American Statistical Association, 53, 457-481.
21. Velasquez, W.S., Cabanillas, F., Salvador, P., McLaughlin, P., Fridrik, M., Tucker, S., et al. (1988) "Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)", Blood, 71, 117-122.
22. Velasquez, W.S., McLaughlin, P., Tucker, S., Hagemeister, F.B., Swan, F., Rodriguez, M.A., et al. (1994) "ESHAP: an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study", Journal of Clinical Oncology, 12, 1169-1176.
23. Proctor, S.J., Taylor, P.R., Angus, B., Wood, K., Lennard, A.L., Lucraft, H., et al. (2001) "High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy", European Journal of Haematology, (Suppl 64), 28-32.
24. Joyce, R.M., Kraser, C.N., Tetrealt, J.C., Giallombardo, N., McDermott, D., Levine, J., et al. (2001) "Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant", European Journal of Haematology, (Suppl 64), 56-62.
25. Kewalramani, T., Zelenetz, A. and Bertino, J. (2001) "Rituximab significantly increases the complete rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)", Blood, 98(Suppl 1), a1459 [abstract].
26. Joyce, R.M., Regan, M., Ottaway, J., Umiel, T., Tetreault, J.C., Levine, J., et al. (2003) "A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT)", Annals of Oncology, 14(Suppl 1), 21-27.